Literature DB >> 23439182

Technical challenges and clinical outcomes of using a closed-loop glycemic control system in the hospital.

Takehiro Okabayashi1, Akihito Kozuki, Tatsuaki Sumiyoshi, Yasuo Shima.   

Abstract

According to large randomized trials, results suggest that maintaining normoglycemia postoperatively through tight glycemic control (TGC) and intensive insulin therapy (IIT) can improve surgical outcomes as well as reduce mortality and morbidity in critically ill patients. However, trials examining the effects of TGC have had conflicting results. Systematic reviews and meta-analyses have also led to differing conclusions. The main reason these clinical trials and meta-analyses show negative results for TGC is the high incidence of hypoglycemia induced by IIT. This could not be prevented because there is no reliable technique that can avoid this condition during IIT. The development of accurate, continuous blood glucose monitoring devices and closed-loop systems for computer-assisted blood glucose control in the intensive care unit (ICU) will probably help avoid hypoglycemia in these situations. The STG closed-loop glycemic control system was introduced to our department to be used and evaluated for strict serum glucose control with no hypoglycemic episodes during IIT in the surgical ICU, to reduce the workload of ICU nurses, and to decrease incidents related to the management of blood glucose levels according to manual conventional venous infusion insulin therapy. The goal of our team was to use the STG closed-loop glycemic control system for perioperative TGC in surgical patients to solve the complications of IIT and reduce risk of hypoglycemia. The challenge at our hospital demonstrated that the STG closed-loop glycemic control system can be expected to achieve TGC with no occurrence of hypoglycemia induced by IIT after surgery.
© 2012 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23439182      PMCID: PMC3692238          DOI: 10.1177/193229681300700129

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  25 in total

1.  Artificial endocrine pancreas.

Authors:  K Hanazaki; Y Nosé; F C Brunicardi
Journal:  J Am Coll Surg       Date:  2001-09       Impact factor: 6.113

Review 2.  Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony.

Authors:  Mark A Herman; Barbara B Kahn
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

3.  Glucose control lowers the risk of wound infection in diabetics after open heart operations.

Authors:  K J Zerr; A P Furnary; G L Grunkemeier; S Bookin; V Kanhere; A Starr
Journal:  Ann Thorac Surg       Date:  1997-02       Impact factor: 4.330

4.  Blood glucose control using an artificial pancreas reduces the workload of ICU nurses.

Authors:  Kiyo Mibu; Tomoaki Yatabe; Kazuhiro Hanazaki
Journal:  J Artif Organs       Date:  2011-09-27       Impact factor: 1.731

5.  Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer.

Authors:  Sarah A Little; William R Jarnagin; Ronald P DeMatteo; Leslie H Blumgart; Yuman Fong
Journal:  J Gastrointest Surg       Date:  2002 Jan-Feb       Impact factor: 3.452

6.  Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures.

Authors:  A P Furnary; K J Zerr; G L Grunkemeier; A Starr
Journal:  Ann Thorac Surg       Date:  1999-02       Impact factor: 4.330

Review 7.  Insulin-based regimens decrease mortality rates in critically ill patients: a systematic review.

Authors:  Jane Langley; Gary Adams
Journal:  Diabetes Metab Res Rev       Date:  2007-03       Impact factor: 4.876

8.  Pancreatic polypeptide administration reduces insulin requirements of artificial pancreas in pancreatectomized dogs.

Authors:  Tetsuya Kono; Kazuhiro Hanazaki; Kazuyuki Yazawa; Satoshi Ashizawa; William E Fisher; Xiao-Ping Wang; Yukihiko Nosé; F Charles Brunicardi
Journal:  Artif Organs       Date:  2005-01       Impact factor: 3.094

9.  Diabetes mellitus is a risk factor for hepatic decompensation in patients with hepatocellular carcinoma undergoing resection: a longitudinal study.

Authors:  Teh-Ia Huo; Wing-Yu Lui; Yi-Hsiang Huang; Gar-Yang Chau; Jaw-Ching Wu; Pui-Ching Lee; Full-Young Chang; Shou-Dong Lee
Journal:  Am J Gastroenterol       Date:  2003-10       Impact factor: 10.864

Review 10.  Glycemic control and prevention of perioperative infection.

Authors:  Juan Jose Blondet; Greg J Beilman
Journal:  Curr Opin Crit Care       Date:  2007-08       Impact factor: 3.687

View more
  5 in total

Review 1.  Critical Care Management of Stress-Induced Hyperglycemia.

Authors:  Ilse Vanhorebeek; Jan Gunst; Greet Van den Berghe
Journal:  Curr Diab Rep       Date:  2018-02-26       Impact factor: 4.810

2.  Feasibility of fully automated closed-loop glucose control using continuous subcutaneous glucose measurements in critical illness: a randomized controlled trial.

Authors:  Lalantha Leelarathna; Shane W English; Hood Thabit; Karen Caldwell; Janet M Allen; Kavita Kumareswaran; Malgorzata E Wilinska; Marianna Nodale; Jasdip Mangat; Mark L Evans; Rowan Burnstein; Roman Hovorka
Journal:  Crit Care       Date:  2013-07-24       Impact factor: 9.097

Review 3.  Managing hyperglycemia during the COVID-19 pandemic: Improving outcomes using new technologies in intensive care.

Authors:  Timothy Valk; Carol McMorrow
Journal:  SAGE Open Med       Date:  2020-11-19

Review 4.  The Hypoglycaemia-Hyperglycaemia Minimizer System in the Management of Type 1 Diabetes.

Authors:  Brian L Levy; Thomas W McCann; Daniel A Finan
Journal:  Eur Endocrinol       Date:  2016-03-15

Review 5.  Improving glycemic control in critically ill patients: personalized care to mimic the endocrine pancreas.

Authors:  J Geoffrey Chase; Thomas Desaive; Julien Bohe; Miriam Cnop; Christophe De Block; Jan Gunst; Roman Hovorka; Pierre Kalfon; James Krinsley; Eric Renard; Jean-Charles Preiser
Journal:  Crit Care       Date:  2018-08-02       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.